Characteristics of liver diseases in the elderly: a review

Minerva Gastroenterologica e Dietologica

Volumn 55, Issue 1, 2009, Pages 71-78

  Premoli, A ^a   Pascheyfa, E ^a   Hvalryg, M ^a   Spandre, M ^a   Bo, S ^a   Durazzo, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Aged; Hepatitis Carcinoma, hepatocellular; Liver diseases; liver transplantation

Indexed keywords

ADEFOVIR; ALENDRONIC ACID; ALPHA FETOPROTEIN; ALPHA INTERFERON; CORTICOSTEROID; ENTECAVIR; HEPATITIS A HEPATITIS B VACCINE; PEGINTERFERON ALPHA; RIBAVIRIN; SORAFENIB; TELBIVUDINE; TENOFOVIR; URSODEOXYCHOLIC ACID;

AGED; AGING; ALCOHOL LIVER DISEASE; AUTOIMMUNE HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DISEASE COURSE; ECHOGRAPHY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER CLEARANCE; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; OSTEOPOROSIS; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; REVIEW; UNSPECIFIED SIDE EFFECT;

AGED; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER DISEASES;

EID: 67649386690     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Anantharaju A, Feller A, Chedid A. Aging Liver. A review. Gerontology 2002;48:343-53
2. Douglas L. Schmucker. Age-related changes in liver structure and function: implications for disease ? Experimental Gerontology 2005;40:650-9.
3. Floreani A. Liver disease in the elderly: an update. Dig Dis 2007;25:138-43.
4. Durazzo M, Premoli A, Bo S. Pellicano R. Gastrointestinal problems in the elderly. Panminerva Med 2007;49:151-8.
5. Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 2005;4l:1151-9.
6. Baldo V, Floreani A, Menegon T, Angiolelli G, Trivello R. Prevalence of antibodies against hepatitis C virus in the elderly: a seroepidemiological study in a nursing home and in an open population. Gerontology 2000;46:194-8.
7. Cainelli F. Hepatitis C virus infection in the elderly: epidemiology, natural history and management. Drugs Aging 2008;25:9-18.
8. Monica F, Lirussi F, Pregun I, Vasile F, Fabris L, Okolicsanyi L. Hepatitis C virus infection in a resident elderly population: a 10-year follow-up study. Dig Liver Dis 2006;38:336-40.
9. Tsui JI, Currie S, Shen H, Bini EJ, Brau N, Wright TL. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci 2008;53:809-l4.
10. Floreani A, Minola E, Carderi I, Ferrara F, Rosa Rizzotto E, Baldo V. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? J Am Geriatr Dis 2006;54:549-50.
11. Honda T, Katano Y, Urano F, Murayama M, Hayashi K, Ishigami M et al. Efficacy of ribavirin plus interferon-alfa in patients aged = 60 years with chronic hepatitis C. J Gastroenterol Hepatol 2007;22:989-95.
12. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M et al. Long-term outcome after Interferon therapy in elderly patients with chronic hepatitis C. Intervirology 20O7;5O:l6-23.
13. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;ll:97-107.
14. Hohler T, Groeger-Bicanic G, Hoet B, Stoffel M. Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults. Vaccine 2007;25:1503-8.
15. Frith J, Jones D, Newton JL. Chronic liver disease in ageing population. Age Ageing 2009;38:ll-8.
16. Merle P, Trepo C, Zoulim F. Current management strategies for hepatitis B in the elderly. Drugs Aging 2001;18:725-35.
17. John W, Culberson MD. Alcohol use in the elderly: beyond the CAGE. Geriatrics 2006;6l:23-7.
18. Seitz HK, Stickel F. Alcoholic liver disease in the elderly. Clin Geriatr Med 2007;23:905-21.
19. Seef LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis. Hepatology 2001;33:455-63.
20. Meier P, Seitz HK. Age, alcohol metabolism and liver disease. Curr Opin Clin Nutr Metab Care 2008;l 1:21-6.
21. El Serag HB. Hepatocellular carcinoma: an epidemio-logic view. J Clin Gastroenterol 2002; 35(5 Suppl 2):s72-78.
22. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005;22:1129-33.
23. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007;22:293-303.
24. Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Faga E et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005;42:1175-83.
25. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
26. Miyaaki H, Ichikawa T, Nakao K, Yatsuhashi H, Furukawa R, Ohba K et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int 2008;28:519-24.
27. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2O03;37:9O9-l6.
28. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut 2007;56:1760-9.
29. Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006;45:575-83.
30. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006;43:532-8.
31. Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I et al. Type I Autoimmune hepatitis: clinical course and outcome in an Italian multi-centre study. Aliment Pharmacol Ther 2006;24:1051-7.
32. Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging 2008;25:219-39.
33. Schramm C, Kanzler S, zum Buschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001;96:1587-91-
34. Newton JL, Jones DE, Metcalf JV, Park JB, Burt AD, Bassendine MF et al. Presentation and mortality of primary biliary cirrhosis in older patients. Age Ageing 2000;29:305-9.
35. Newton J, Francis R, Prince M, James O, Bassendine M, Rawlings D et al. Osteoporosis in primary biliary cirrhosis revisited. Gut 2001;9:282-7.
36. Pares A, Guanabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis 2008;12:407-24.
37. Floreani A, Variola A, Niro G, Premoli A, Baldo V, Gambino R et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am J Gastroenterol 2008;103:1959-65.
38. Silveira MG, Suzuki A, Lindor KD. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 2008;48:1149-56.
39. Mendes FD, Kim WR, Pedersen R, Therneau T, Lindor KD. Mortality attributable to cholestatic liver disease in the United States. Hepatology 2008;47:1241-7.
40. Pares A, Caballeria L, RodesJ. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715-20.
41. Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001;33:22-7.
42. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007;13:1236-45.
43. El Serag HB. Hepatocellular carcinoma: recent trend in the United States. Gastroenterology 2004;127:s27-34
44. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004;53:744-9.
45. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004;10(2 suppl 1):S69-S73.
46. Yeh CN, Lee WC, Jeng LB, Chen MR Hepatic resection for hepatocellular carcinoma in elderly patients. Hepatogastroenterology 2OO4;51:219-23.
47. Suarez Y, Franca AC, Llovet JM, Fuster J, Bruix J. The current status of liver transplantation for primary hepatic malignancy. Clin Liver Dis 2000;4:591-605.
48. El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006;44:158-66.
49. Llovet JM, Ricci S, Mazzaferro V, Hilgard P. Gane E. Blanc JF et al. Sorafnib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
50. Collins BH, Pirsch JD, Becker YT, Hanaway MJ, Van der Werf WJ, D'Alessandro AM et al. Long-term results of liver transplantation in older patients 60 years of age and older. Transplantation 2000;70:780-3.
51. Levy MF, Somasundar PS, Jennings LW, Jung GJ. Molmenti EP, Fasola CG et al. The elderly liver transplant recipient: a call for caution. Ann Surg 2001;233:107-13.
52. Randall HR, Cao S, DeVera ME. Transplantation in elderly patients. Arch Surg 2003;138:1089-92.